Veradermics 10-Q: $798.4M Cash Into 2030, Q3 Loss $21.0M, New 10b5-1 Plans
MANE has more than doubled off its 52-week low of $32.
Summary
Veradermics' Q3 10-Q details a $21.0M quarterly loss and $798.4M in cash and securities it says funds operations into 2030, plus new 10b5-1 selling plans for two executives and a September 2026 patent review petition.
Key Events · Earnings and Guidance · MANE
-
Q3 Loss and Cash Confirmed in Full 10-Q
Net loss of $20,999 thousand for the quarter and $71,733 thousand for nine months, with $798.4 million in cash, cash equivalents and marketable securities at September 30, 2026.
-
Runway Stated Into 2030
Management says existing cash and securities fund operating expenses and capital expenditures into 2030; nine-month operating cash burn was $58,603 thousand versus $47,974 thousand a year earlier.
-
Two New Executive Selling Plans
Mark Neumann adopted a Rule 10b5-1 plan on 08/13/2026 for up to 80,000 shares and CFO Dominic Carrano adopted one on 09/21/2026 for up to 42,000 shares, both sales beginning in December 2026.
-
Patent Post-Grant Review Petition Disclosed
A third party filed a petition in September 2026 seeking post-grant review of one of the company's issued U.S. patents; the company says it intends to defend the patent vigorously.
Analysis · MANE · Life Sciences
The headline numbers were pre-released in this morning's 8-K, so the loss and cash balance are not new. What the full 10-Q adds is the detail behind them: nine-month operating cash burn of $58.6M against a $798.4M cash and securities pile that management says funds operations into 2030, which removes any near-term financing need even as R&D and pre-commercial G&A spending climb. It also puts two new insider selling plans on the record — the Chief Commercial and Strategy Officer for up to 80,000 shares and the CFO for up to 42,000 — and discloses that a third party filed a post-grant review petition in September 2026 against one of the company's issued U.S. patents, a patent risk that was not previously public.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MANE was trading at $148.44 on NYSE in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $32.00 to $152.82. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.